CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine + AzithromycinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug852 Placebo + Placebo Wiki 0.71
drug509 Hydroxychloroquine + Placebo Wiki 0.71
drug131 BNT162b1 Wiki 0.50
drug133 BNT162c2 Wiki 0.50
drug130 BNT162a1 Wiki 0.50
drug132 BNT162b2 Wiki 0.50
drug505 Hydroxychloroquine Wiki 0.08

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D012327 RNA Virus Infections NIH 0.35
D012141 Respiratory Tract Infections NIH 0.16
D003141 Communicable Diseases NIH 0.15
D007239 Infection NIH 0.10
D014777 Virus Diseases NIH 0.10
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0011947 Respiratory tract infection HPO 0.16

There are 2 clinical trials

Clinical Trials

1 Qatar Prospective RCT Of Therapy Eliminating Covid Transmission

Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.

NCT04349592 Covid19 Drug: Hydroxychloroquine + Azithromycin Drug: Hydroxychloroquine + Placebo Other: Placebo + Placebo

Primary Outcomes

Description: Days

Measure: Proportion of virologically cured (no virus detected) cases at day 6

Time: Day 6

Secondary Outcomes

Description: Days

Measure: The dichotomous virologic shedding endpoint as assessed at two weeks after study entry

Time: 2 weeks

Description: Days

Measure: Quantitative viral load (assessed with each virology testing set)

Time: Day 1 to 21

2 Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal

COVID-19 is an emerging pandemic disease affecting most countries including Senegal, caused by the new coronavirus (SARS-CoV-2) which was first detected in the city of Wuhan in China in December 2019. A rapid spread of the disease has occurred at a global scale, associated with a mortality rate of 3.4%. The first case in Africa was declared on February 15, 2020 in Egypt and the first case in Senegal was declared on March 2nd, 2020. In this context, the SEN-CoV-Fadj clinical trial aims to evaluate efficacy and safety, among adults, of different therapeutic regimens considered optimal according to current knowledge, as well as available and adapted to Sub-Saharan Africa. This trial is nested into a cohort of confirmed cases of COVID-19 in Senegal aiming to understand the main clinical, biological, virologic and immunological characteristics of the infection. The protocol of the cohort is based and adapted from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) / World Health Organization (WHO) Clinical Characterisation Protocol (CCP). Two therapeutic regimens have been eligible in the short term for SEN-CoV-Fadj: Hydroxychloroquine (HCQ) on one hand, and the combination of Hydroxychloroquine and Azithromycin (HCQ + AZM) on the other hand.

NCT04390594 COVID-19 Drug: Hydroxychloroquine Drug: Hydroxychloroquine + Azithromycin

Primary Outcomes

Description: Real time-PCR (RT-PCR) result of the naso- and oro-pharyngeal sample

Measure: SARS-CoV-2 viral load level

Time: Day 7

Secondary Outcomes

Measure: Vital status

Time: Day 15

Measure: Proportion of patients with serious adverse events reported during the clinical trial.

Time: through study completion, an average of 7 months

Measure: Length of hospitalization

Time: through hospitalization, an average of 2 weeks

Measure: Length of hospitalization in a resuscitation unit

Time: through hospitalization, an average of 2 weeks

Measure: Duration of oxygen therapy

Time: through hospitalization, an average of 2 weeks

Measure: Maximum quick SOFA (qSOFA) score during hospitalisation

Time: through hospitalization, an average of 2 weeks

No related HPO nodes (Using clinical trials)